A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of oral vismodegib for the treatment of idiopathic pulmonary fibrosis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2015
Price : $35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms ISLAND
- Sponsors Roche
- 01 Dec 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 19 Aug 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 04 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.